CLINICAL AND ECONOMIC CONSEQUENCES OF ESPRIT BTK VERSUS BALLOON ANGIOPLASTY IN CHRONIC LIMB-THREATENING ISCHEMIA: A FRENCH COST-CONSEQUENCE ANALYSIS
Author(s)
Radia Lamramri, PharmD, MSc1, Bertrand Tehard, MSc, PhD2, Giota Veliu, PharmD3.
1ABBOTT, Paris, France, 2Scientific Director, Vyoo Agency, Paris, France, 3ABBOTT, Zaventem, Belgium.
1ABBOTT, Paris, France, 2Scientific Director, Vyoo Agency, Paris, France, 3ABBOTT, Zaventem, Belgium.
OBJECTIVES: To estimate the clinical and economic consequences associated with Esprit BTK everolimus-eluting bioresorbable scaffold versus percutaneous transluminal angioplasty (PTA) for the treatment of infrapopliteal lesions in patients with chronic limb-threatening ischemia (CLTI). The analysis focused on care pathways and healthcare resource utilization excluding device acquisition costs, which remain under negotiation
METHODS: A 3-year 3-healthstate Markov model was developed from the French healthcare system perspective, including: (1) Index revascularization, (2) first repeat revascularization (RR1), and (3) death. Restenosis, second repeat RR2, and major amputation were modelled as intercurrent events Transition probabilities for restenosis and RR1 were derived from LIFE-BTK trial 2-year data. Other subsequent probabilities were extracted from a literature data. No impact on major amputation and mortality was modelled in the base case scenario. French Diagnosis-Related Group tariffs informed hospitalization and management costs. Sensitivity analyses were conducted to explore different scenarios
RESULTS: Esprit BTK decreased restenosis and RR occurrence by 32.2% and 49.7% respectively, versus PTA. Hospitalization burden decreased by 35.5% with Esprit-BTK leading to an average hospital length of stay of 2.7 versus 4.2 days with PTA. Mean time to restenosis and RR1 increased by 4.2 and 1.9 months, respectively. Treating only 11 patients with Esprit-BTK is needed to avoid 1 restenosis and RR.Including a post RR1 impact on major amputation and mortality, it is expected that ESPRIT-BTK could decreased major amputation and death occurrence by 47.3% and 12.9% respectively.ESPRIT-BTK can decrease total costs by 7,4% over 3 years. The main driver of this savings is the reduction in repeat revascularisation/RR (71.8% of the savings). For a single cohort of 1,000 patients benefiting from ESPRIT-BTK, 712 k€ can be saved over 3 years
CONCLUSIONS: Esprit BTK can substantially reduce subsequent clinical burden and healthcare resource utilization in patients with CLTI and consequently generate important healthcare organizational and economic benefits
METHODS: A 3-year 3-healthstate Markov model was developed from the French healthcare system perspective, including: (1) Index revascularization, (2) first repeat revascularization (RR1), and (3) death. Restenosis, second repeat RR2, and major amputation were modelled as intercurrent events Transition probabilities for restenosis and RR1 were derived from LIFE-BTK trial 2-year data. Other subsequent probabilities were extracted from a literature data. No impact on major amputation and mortality was modelled in the base case scenario. French Diagnosis-Related Group tariffs informed hospitalization and management costs. Sensitivity analyses were conducted to explore different scenarios
RESULTS: Esprit BTK decreased restenosis and RR occurrence by 32.2% and 49.7% respectively, versus PTA. Hospitalization burden decreased by 35.5% with Esprit-BTK leading to an average hospital length of stay of 2.7 versus 4.2 days with PTA. Mean time to restenosis and RR1 increased by 4.2 and 1.9 months, respectively. Treating only 11 patients with Esprit-BTK is needed to avoid 1 restenosis and RR.Including a post RR1 impact on major amputation and mortality, it is expected that ESPRIT-BTK could decreased major amputation and death occurrence by 47.3% and 12.9% respectively.ESPRIT-BTK can decrease total costs by 7,4% over 3 years. The main driver of this savings is the reduction in repeat revascularisation/RR (71.8% of the savings). For a single cohort of 1,000 patients benefiting from ESPRIT-BTK, 712 k€ can be saved over 3 years
CONCLUSIONS: Esprit BTK can substantially reduce subsequent clinical burden and healthcare resource utilization in patients with CLTI and consequently generate important healthcare organizational and economic benefits
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
MT22
Topic
Economic Evaluation, Health Technology Assessment, Medical Technologies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)